featured
First-Line Pertuzumab Plus Trastuzumab Plus a Taxane for HER2-Positive Locally Recurrent or Metastatic Breast Cancer
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Annals of Oncology
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Final Results From the PERUSE Study of First-Line Pertuzumab Plus Trastuzumab Plus a Taxane for HER2-Positive Locally Recurrent or Metastatic Breast Cancer, With a Multivariable Approach to Guide Prognostication
Ann. Oncol 2021 Jul 02;[EPub Ahead of Print], D Miles, E Ciruelos, A Schneeweiss, F Puglisi, T Peretz-Yablonski, M Campone, I Bondarenko, Z Nowecki, H Errihani, S Paluch-Shimon, A Wardley, JL Merot, P Trask, Y du Toit, C Pena-Murillo, V Revelant, D Klingbiel, T BachelotFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.